Just in time for the 2003/2004 flu season, clinicians will be able to offer their "needle phobic" patients the first cold-adaptive, live-attenuated influenza vaccine (CAIV) that is administered as a nasal spray. The FDA recently approved influenza virus vaccine live, intranasal (FluMist, MedImmune Vaccines/Wyeth Vaccines) for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, 5 to 17 years old, and healthy adults, 18 to 49 years old. The vaccine will be available in pharmacies beginning in the late summer to early fall.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.